Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Plain-language summary

This study examines, based on historical data, the weekly use of a first-generation EGFR-TKI in patients with non-small cell lung cancer (NSCLC) who have developed acquired resistance to first-generation EGFR-TKI therapy. NSCLC patients with an EGFR mutation whose disease progressed after a first-generation EGFR-TKI were included. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Qingdao Central Hospital

Intervention

history data

Start date

10/1/2015

Estimated completion

12/31/2017

Countries

China

Related genes

Locations

• Qingdao, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* NSCLC with EGFR mutation progressed after first generation EGFR-TKI, or progressed after chemotherapy and 1st generation EGFR-TKI or progressed after 1st generation EGFR-TKI and chemotherapy. Expected survival more than 3 months with a ECOG ≤3.

Exclusion Criteria:

* liver function (ALT, AST) and renal function 2 times higher than normal limit; IPD; uncontrolled diarrhea; severe anemia.